57results about How to "Increase route of administration" patented technology

The invention discloses a fusion protein of a novel coronavirus envelope protein and an application of the fusion protein. The fusion protein (SARS2-RBD-Fc) is obtained by fusing an RBD structural domain of a novel coronavirus envelope protein S with an antibody Fc fragment; and as a subunit vaccine, the fusion protein can induce an organism to generate an efficient neutralizing antibody through nasal drip immunization and intramuscular injection. It indicates that the SARS2-RBD-Fc can be used as a candidate vaccine for preventing and treating new coronavirus infection.

This invention relates to novel human monoclonal antibodies (mAbs) and to the genes encoding same. More specifically, this invention relates to human monoclonal antibodies specifically reactive with an epitope of the fusion (F) protein of Respiratory Syncytial Virus (RSV). Such antibodies are useful for the therapeutic and/or prophylactic treatment of RSV infection in human patients, particularly infants and young children.

The invention relates to the following general formula compound (I) and use of the general formula compound in preparing anti-inflammatory and anti-endotoxin medicines. In formula I, R is an acid solubilizing side chain of hydroxide radical in an arctigenin molecule, and can be an acid group or side chain imported through alkylation reaction or acylating reaction, such as sulphonic acid ester, sulfuric acid ester, organic phosphate, succinate, propionic ether, butyric ester, semi-succinate, semi-glutaric acid ester, semi-tartrate, semi-phthalic acid ester, m-benzene sulfonic acid ester and so on.

The invention relates to a streptococcus faecium function signal molecule preparation, a streptococcus faecium bacteria strain is carried out the anaerobic fermentation at 35 to 38 DEG C and the centrifugal concentration to obtain a concentrate of streptococcus faecium bacteria, the bacterial cell wall is broken by high pressure, and the freeze-drying is carried out to obtain the preparation raw powder containing the streptococcus faecium function signal molecules. As the streptococcus faecium function signal molecules can be combined with a specific receptor at the intestinal epithelial cells, the issued signal can induce the excessive cholesterol in the body to carry out the transformation, control the activity of the cholesterol synthase, reduce the excessive cholesterol generated or absorbed in the human body, and effectively control the obesity. The streptococcus faecium function signal molecule preparation is simultaneously matched with a bifidobacterium function signal molecule preparation, a lactobacillus function signal molecule preparation and a bacteroides function signal molecule preparation to be prepared into a series of products containing various probiotics function signal molecules for lipid-lowering and weight-losing, thus fundamentally reducing the risks of coronary heart disease, atherosclerosis, heart diseases, angina, myocardial infarction, obesity and other diseases during the process of being eaten by the people.

The invention discloses a beta-cyclodextrin inclusion compound of huperzine A, and a preparation method and preparations thereof. The beta-cyclodextrin inclusion compound of the huperzine A consists of 2.5 to 9.5 weight percent of huperzine A and 97.5 to 90.5 weight percent of beta-cyclodextrin. The preparation method comprises the following steps of: a) dissolving the huperzine A in an pharmaceutically acceptable organic solvent to prepare solution A, and heating and dissolving the beta-cyclodextrin in water to prepare solution B; and b) slowly adding the solution A into the solution B with stirring, and continuing to perform stirring until the mixed solution is uniform to prepare the beta-cyclodextrin inclusion compound of the huperzine A. The beta-cyclodextrin inclusion compound of the huperzine A further can be mixed with water-soluble carriers with viscosity, such as starch and the like, and then is pelletized, tabletted or filled into capsules with substrates. In the method, an extremely small amount of water-insoluble huperzine A is fully, effectively and uniformly dispersed, so the dissolution rate of the huperzine A is increased and the stability of the huperzine A is improved. The provided beta-cyclodextrin inclusion compound of the huperzine A can be used for preparing solid preparations and liquid preparations, operating steps are reduced and the production cost is remarkably reduced.

An navel plaster is prepared from 15 Chinese-medicinal materials including atractylodes rhizome, bitter orange, agastache, cloves, etc. Its preparing process is also disclosed.

The invention belongs to the field of medical embolization devices, relates to a sodium alginate microsphere targeted vascular embolization agent containing an antineoplastic drug and a preparation method thereof. Alginic acid is taken as a pharmaceutical carrier, the antineoplastic drug etoposide is a pharmaceutical active ingredient, divalent metal cation or calcium ion solution is taken as a solidifying agent, and the sodium alginate encapsulates the etoposide to prepare ideal particle size-controllable sodium alginate microspheres comprising the etoposide, thus avoiding toxic side effect of traditional etoposide administration such as anaphylaxis and inconvenience. The vascular embolization agent changes the dosage form and route of administration way of the antineoplastic drug etoposide, has high efficacy and low toxicity, and is safely and effectively applied to clinical application. The vascular embolization agent has the advantages of mild preparation condition and simple and convenient operation, and is fit for large-scale production. The vascular embolization agent can be used for vascular embolization, local targeted tumor treatment, and treating small-cell carcinoma of the lung, oophoroma, carcinoma of testis, gastric cancer and liver cancer by administering the vascular embolization agent during operations.

The invention provides an application of morusin or its pharmaceutically acceptable derivative in preparation of medicines for resisting malignant tumor. The invention also provides an application of morusin or its pharmaceutically acceptable salt in preparation of anti-glioma medicines. It is found through researches that morusin shows a good activity of resisting malignant tumor (such as glioma) in vitro and in vivo. In addition, it shows through experiments that morusin has a good effect of suppressing tumor growth and inducing transversal differentiation and apoptosis of tumor cells and tumor stem cells, and has little toxic and side effect on normal cells. The morusin has a good application prospect.

The invention belongs to the field of bio-medicines, and particularly relates to an application of a hemopoietin sourced peptide in preparation of a medicine for treating the metabolic syndrome. The application includes an application of preparation of medicines for treating obesity, diabetes mellitus and hyperlipemia, The hemopoietin sourced peptide can be prepared into lipidosome, and the metabolic syndrome can be treated by the hemopoietin sourced peptide and the hemopoietin sourced peptide lipidosome, the syndromes of the hemopoietin sourced peptide are remarkably relieved after treatment, and the effect of the hemopoietin sourced peptide lipidosome is superior to that of the hemopoietin sourced peptide, and the administration frequency can be reduced. The application of the hemopoietin sourced peptide lipidosome to medicines can be used for prolonging the medicine acting period, increasing the lipid solubility and stability of the medicines and reducing toxic and side effects. Therefore, compared with an independent application of micro-molecule polypeptide, lipidosome coated micro-molecule polypeptide has the advantages of prolonging half-life period, improving stability and lipid solubility and increasing administration routes. The hemopoietin sourced peptide has an important clinical application value.

An imidazole compound represented by the formula (I), a salt thereof and a compound of the formula (V), which is one of the intermediates thereof. wherein each symbol is as defined in the present specification. The compound of the present invention shows a superior anti-ulcer activity, a gastric acid secretion inhibitory action, a mucosa-protecting action, an anti-Helicobacter pylori action and the like. Since it shows low toxicity, the compound is useful as a pharmaceutical product.

The present invention relates to complex salt or composition medicine of breviscapine and basic amino acid for treating cardiac and cerebral vascular diseases. The composition medicine consists of breviscapine 1 weight portions, and basic amino acid 0.01-100 weight portions, and proper amount of supplementary material. It may be prepared into powder for injection, injection, oral liquid, capsule and other suitable clinical preparation forms. The composition medicine of the present invention has obviously raised dissolubility and bioavailability of breviscapine, high medicine effect, obvious synergistic effect and wide clinical application foreground.

The invention provides a cucurbitacin medicinal composition and pharmaceutical application thereof. The cucurbitacin medicinal composition comprises cucurbitacin, a solubilizer, an antioxidant and a pH regulator, wherein the using amount of the pH regulator is enough for regulating the pH value of the medicinal composition to 3.5-7.5; the weight ratio of the cucurbitacin to the solubilizer is (1:600)-(1:3,150). The medicinal composition can be used for preparing medicaments for lowering the toxicity of cucurbitacin as well as anti-hepatitis, jaundice-removing and anti-cancer medicaments.

The invention discloses resveratrol external use gel and a preparation method thereof. The resveratrol external use gel is prepared from the following materials: 0.01 percent to 5 percent of resveratrol, 0.2 percent to 1.5 percent of carbomer, 5 percent to 15 percent of propanediol, 0.01 percent to 0.1 percent of sodium pyrosulfite, 0.5 percent to 2.0 percent of triethanolamine, 0.05 percent to 1 percent of methyl p-hydroxybenzoate, 0.02 percent to 2 percent of laurocapram and 73.4 percent to 94.21 percent of pure water. A modern preparation technology is used; the resveratrol external use gel is prepared by taking the carbomer as a gel substrate;; the medication route of the resveratrol is expanded; the bioavailability of the medicine for treating body surface skin diseases is improved. The resveratrol external use gel is suitable for human skin and mucosa local medication. Compared with oral medication, the resveratrol external use gel has the advantages that the effective blood concentration of local affected parts is greatly improved; the medicine bioavailability is improved.

The invention discloses a ketoprofen solution. The ketoprofen solution comprises the following components in every 100mL: 0.1-1g of ketoprofen, 0.1-10g of sodium acetate, glacial acetic acid used for regulating the pH value to 5.5-6.5, and the balance of injection water. A preparation method of the ketoprofen solution comprises the following steps: adding the sodium acetate with the prescribed amount into 50-80mL of injection water, uniformly stirring and mixing; adding ketoprofen with the prescribed amount into the mixture, stirring under a condition of 50+/-5 DEG C until the ketoprofen is completely dissolved; cooling the liquid medicine to room temperature, and regulating the pH value to 5.5-6.5 with glacial acetic acid; fixing the volume to 100mL by using the injection water, uniformly mixing, and filtering. According to the ketoprofen solution, the sodium acetate is used as a cosolvent of ketoprofen, so that the defect of an existing ketoprofen cosolvent can be overcome; the sodium acetate and the glacial acetic acid or ketoprofen form a buffering pair, and play an important role in stabilizing the pH value of the solution; the ketoprofen solution is simple in preparation process, good in repeatability and low in cost, is suitable for industrial large-scale production, does not contain an organic solvent, benzyl alcohol or other component, is safer in clinical application, can be produced into an oral solution and small-dose injection, as well as a preparation for venous transfusion.

Levo-ulifloxacin injection and preparation method thereof, relate to pharmaceutical preparations containing fluoroquinolone antibacterial drugs, in particular to injection of prulifloxacin active body Ulifloxacin (S-(-)-Ulifloxacin) and preparation thereof method. The present invention is based on (S)-(-)-6-fluoro-1-methyl-4-oxo-7-(1-piperazinyl)-1H, 4H-[1,3]thiazetidine Alkane[3,2-a]quinoline-3-carboxylic acid (levofloxacin for short) is the active ingredient of the drug, and the rest are pharmaceutically acceptable additives for injections, which are liquid injections or solid injections Injections, wherein each injection or bottle contains 10-100 mg of active pharmaceutical ingredients. The commonly used dose in clinic may be 10-100 mg of levofloxacin, once or twice a day; 1-10 ml for intramuscular injection and 50-1000 ml for intravenous injection. The invention increases the route of administration, expands the range of application groups, and significantly reduces the cost and risk of medication for patients.

The invention provides an application of an SOX2 targeted drug to inhibiting proliferation of lung cancer stem cells. The SOX2 targeted drug is a scutellaria barbata D.Don extract; and the SOX2 targeted drug interferes with proliferation of lung cancer stem cells and multidrug resistance thereof through targeted inhibition of SOX2. The drug has toxic and side effects, and is tolerable and easy totake orally and absorb. Cell proliferation, cell apoptosis and cell cycle arrest assays prove that a polypeptide provided by the invention can effectively inhibit proliferation of tumor stem cells andthe drug has no obvious tissue damage or toxicity to mice at high doses.